Wearable glucose sensor to check for diabetes after gestational diabetes
Tests a 14-day wearable glucose sensor after pregnancy in women who had gestational diabetes.
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Registry title
- Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening
- Status
- Enrolling by invitation
- People taking part
- 1,300 people, planned
- Started
- 6 Jul 2026
- Expected to end
- Jan 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 or older who had gestational diabetes (diabetes during pregnancy) in their most recent pregnancy. They must be 12-16 weeks after giving birth.
- Age
- 18 Years and older
- Sex
- Female
- Disease stage
- Gestational diabetes diagnosed in the most recent pregnancy; now 12-16 weeks after birth.
- Biomarker or test result
- An order for an Oral Glucose Tolerance Test (OGTT, a sugar-drink blood test) must be in the medical record.
Main reasons for not taking part
- Diabetes that started before the pregnancy
- Not speaking English
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- 12-16 weeks postpartum
- Gestational diabetes Mellitus (GDM) diagnosis in most recent pregnancy
- Oral Glucose Tolerance Test (OGTT) order placed in the medical record
Who cannot take part
- Pre-gestational diabetes
- Non-English language
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
The oral glucose tolerance test (OGTT) is the standard of care in the postpartum period to screen patients with gestational diabetes mellitus (GDM) for persistent dysglycemia. However, most patients find it burdensome and dread having to do it. Adherence rates are low (18-61%), impeding initiation of follow-up care to improve diabetes-related outcomes in subsequent pregnancies and long-term.
The 3 groups in the trial
- Postpartum CGMExisting treatment, for comparison
Postpartum continuous glucose monitoring
Treatment: Continuous glucose monitoring for 14 days using the Freestyle LibrePro by Abbott
- Postpartum OGTTNo study treatment, for comparison
Postpartum oral glucose tolerance test
- No screeningNo study treatment, for comparison
No postpartum glucose screening
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening
- Plain-language title
- Wearable glucose sensor to check for diabetes after gestational diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 10 July 2026